Ginsenoside Rd

Summary

Ginsenoside Rd (CHEMBL473659) is a phase-3 clinical-stage oligosaccharide neuroprotective agent; indicated across 1 condition.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Oligosaccharide
• Indications: 1 condition
• Clinical trials: 2
• Chemistry: 947.2 Da · C48H82O18

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL473659
Name	Ginsenoside Rd
Type	Oligosaccharide
Max phase	3
FDA approved	no
PubChem CID	11679800
ChEBI	CHEBI:67988
Molecular formula	C48H82O18
Molecular weight	947.2
InChIKey	RLDVZILFNVRJTL-IWFVLDDISA-N

SMILES: CC(=CCC[C@@](C)([C@H]1CC[C@@]2([C@@H]1[C@@H](C[C@H]3[C@]2(CC[C@@H]4[C@@]3(CC[C@@H](C4(C)C)O[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)CO)O)O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O)C)C)O)C)O[C@H]7[C@@H]([C@H]([C@@H]([C@H](O7)CO)O)O)O)C

IUPAC name: (2S,3R,4S,5S,6R)-2-[(2R,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-2-[[(3S,5R,8R,9R,10R,12R,13R,14R,17S)-12-hydroxy-4,4,8,10,14-pentamethyl-17-[(2S)-6-methyl-2-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhept-5-en-2-yl]-2,3,5,6,7,9,11,12,13,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl]oxy]oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol

ChEBI definition: A ginsenoside found in Panax ginseng and Panax japonicus var. major that is (20S)-ginsenoside Rg3 in which the hydroxy group at position 20 has been converted to its β-D-glucopyranoside.

Pharmacological roles (ChEBI): vulnerary, neuroprotective agent, apoptosis inducer, anti-inflammatory drug, immunosuppressive agent.

Other ChEBI roles (chemical / environmental): plant metabolite.

Also known as: Chikusetsusaponin fk7, Ginsenoside rd, Gypenoside viii, ginsenoside Rd, ginsenoside-Rd, Ginsenoside Rd, GINSENOSIDE RD

Patent coverage: 1,029 distinct patent families (1,735 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: AMPK alpha2/beta1/gamma1.

Bioactivity

ChEMBL activities: 1 potent at pChembl ≥ 5 of 1 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
PRKAG1	7.78	EC50	16.8	nM	CHEMBL_ACT_18451468

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication record carries no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 2.

Phase distribution

Phase	Trials
PHASE3	1
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00815763	PHASE3	COMPLETED	Efficacy and Safety of Ginsenoside-Rd for Acute Ischemic Stroke
NCT00591084	PHASE2	COMPLETED	Ginsenoside-Rd for Acute Ischemic Stroke

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).